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Abstract
BACKGROUND/AIMS: Acetaminophen overdose causes hepatotoxicity mediated by toxic metabolites generated
through the cytochrome P450 enzyme. The objective of this study was to investigate whether acetaminophen
(AAP) can enhance cisplatin (CDDP) cytotoxicity against human hepatocarcinoma and hepatoblastoma cells in vitro
and whether this effect can be prevented by N -acetylcysteine (NAC). METHODS: In vitro studies (glutathione [GSH]
level, cell viability, and immunoblot assays) were performed using human hepatocarcinoma and hepatoblastoma cells
cultured in AAP, CDDP, and the combination of both with or without delayed NAC administration. The pharmacology
and toxicology of high-dose AAP in rats were also examined. RESULTS: Acetaminophen decreased GSH levels in liver
cancer cells in a dose- and time-dependent manner. Acetaminophen combined with CDDP had enhanced cytotoxicity
over CDDP alone. The cytotoxicity caused by AAP plus CDDP was decreased by NAC, with the effectiveness being
time-dependent. The GSH level was lowered in the liver but not in the blood or the brain in rats treatedwith a high dose
of AAP (1000mg/kg). The expression of CYP2E1 protein, a key cytochrome P450 enzyme, varies among species but is
not correlated to AAP sensitivity in liver cancer cells. CONCLUSIONS: Our results suggest that a chemotherapeutic
regimen containing both AAP and CDDP with delayed NAC rescue has the potential to enhance chemotherapeutic
efficacy while decreasing adverse effects. This would be a promising approach particularly for hepatoblastomas
regardless of cellular CYP2E1 protein level but could also be beneficial in other malignancies.
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Introduction
Hepatoblastoma (HB) is the most common tumor of the liver observed
in pediatric patients and accounts for 0.9% of all pediatric solid tumors
[1]. Currently, a wide range of chemotherapeutic agents is being used in
the treatment of HB presenting patients, including irinotecan, vin-
cristine, 5-fluorouracil, doxorubicin, and cisplatin (CDDP) [2]. The
use of such treatment options, applied in combination with surgical
resection, has resulted in overall survival rates in standard-risk cases
of greater than 90% [3]. However, treatment options for high-risk
and recurrent disease remain less than satisfactory, and chemotherapy
regimens with improved efficacy are needed [4]. CDDP, a common
platinum-based agent, is effective against a broad spectrum of cancer
malignancies. CDDP forms both intrastrand and interstrand cross-links
of DNA, thus shielding the DNA from repair mechanisms and leading
the cell into autophagy and apoptosis [5]. CDDP causes covalent cross-
links on both proteins and DNA [6]. The causes of tumor cell resis-
tance to CDDP and its analogs (i.e., carboplatin and oxaloplatin) are
incompletely understood, and the various analogs differ in their degree
of cross-resistance with CDDP in experimental tumor systems. A major
cause of CDDP resistance seems to be inactivation of the drug by
endogenous thiols, including glutathione (GSH) and other sulfhydryls
such asmetallothionein [7].One study found that low levels ofmessenger
RNA for GSH S-transferase inversely correlate with high sensitivity to
CDDP and carboplatin [8]. Another study developed a CDDP-resistant
human small cell carcinoma cell line that was found to have significantly
increased levels of GSH when compared with the CDDP-sensitive cell
lines [9].
Acetaminophen (AAP, paracetamol) is a commonly used analgesic and
antipyretic drug. When administered in high doses, AAP proved to be
cytotoxic to hepatocytes and other cells containing mixed-function oxi-
dase. The mixed-function oxidase system of enzymes (most relevantly
cytochrome P450 2E1 [CYP2E1]) generates a reactive arylating inter-
mediate that is normally detoxified by reduced GSH [10]. Large doses
of AAP overwhelm GSH stores allowing the toxic metabolite, N -acetyl-
p-benzoquinonimine (NAPQI), to bindmacromolecules and induce cell
death [11]. AAP has been shown to decrease intracellular GSH levels in
different cell types [12–15]. There is evidence that AAP administration
has a wide range of activity against many different tumor types that con-
tain the mixed-function oxidase system [16].
N -acetylcysteine (NAC) is the US Food Drug Administration–
approved antidote for AAP toxicity when given within 8 hours [17]
but has also been shown to be protective against platinum-based
chemotherapy-associated myelotoxicity, ototoxicity, hepatotoxicity,
nephrotoxicity, and neuropathy. In animal models, NAC can prevent
platinum-induced myelotoxicity, neuropathy, nephropathy, and oto-
toxicity when administered intravenously at doses significantly higher
than the standard protocol [18,19]. The mechanism of action for this
protection is unclear; however, it likely acts by inducing synthesis of
GSH [20], by scavenging free radicals directly [21], or by serving as
a substrate for direct chemical conjugation and detoxification [22].
However, whereas NAC has been shown to neutralize the cytotoxicity
of various chemotherapeutic agents, it does not compromise chemo-
therapy efficacy in a rat brain tumor two-compartment model, where
NAC was administered at time points both before and after a three-
drug chemotherapy cocktail (carboplatin, melphalan, and etoposide
phosphate) [23].
Kobrinsky et al. [24] reported a clinical case of an African American
girl with unresectable stage III HB who had failed front-line CDDP-
based therapies. This patient was disease-free 7 years after surgery after
receiving a treatment regimen that combined CDDP after high dose of
AAP and followed with NAC 8 hours later. The intent of this study was
to explore whether AAP has a dual effect on HB cell lines by directly
inducing apoptosis, and/or by decreasing intracellular GSH levels, thus
enhancing CDDP-mediated cytotoxicity. This study also examined
whether the delayed administration of NAC after combination therapy
of AAP and CDDP would be capable of inhibiting therapy-related
adverse effects. These results may provide clinically relevant infor-
mation about a potential chemotherapeutic regimen in which AAP,
combined with CDDP with delayed NAC rescue, can be used for the
treatment of high-risk HB or other malignancies.
Materials and Methods
Pharmacological Agents and Antibodies
Sterile solutions of CDDP and NAC were obtained from the Medi-
cal University of Gdansk pharmacy. Acetaminophen and mouse anti-
tubulin antibody were purchased from Sigma (St Louis, MO). Rabbit
anti-poly ADP ribose polymerase (PARP) was purchased from Cell Sig-
naling through New England BioLabs (Frankfurt, Germany). Rabbit
anti-CYP2E1 polyclonal antibody was from Stressgen (Ann Arbor, MI).
Cell Culture
Human HepG2 hepatocarcinoma and HUH6 and HepT1 HB cell
lines were obtained from Dr. Steven Warmann (Tuebingen, Germany)
and were cultured in Dulbecco’s modified Eagle medium in 10% FBS
and 1% streptomycin/penicillin cocktail (Sigma-Aldrich, Poznan,
Poland). Cells were maintained at 37°C and in an atmosphere con-
taining 5% CO2. Normal human hepatocytes were obtained through
Liver Tissue Cell Distribution System (Pittsburgh, PA), which was
funded by the National Institutes of Health contract no. N01-DK-7-
0004/HHSN26700700004C.Normal rat and mouse hepatocytes were
obtained from the Department of Comparative Medicine of Oregon
Health & Science University.
Cell Viability Assay
Cell viability was determined using a WST-1 Cell Proliferation
Assay Kit obtained from Millipore (Warsaw, Poland) following a pre-
viously outlined protocol [25]. In preparation for experiments, cells
were trypsinized, collected, and then plated in 96-well plates. One
day later, the cells were treated with NAC, AAP, and/or CDDP. After
an incubation period of 18 to 24 hours, 10 μl of WST-1 reagent was
added to each of the wells, and 2 hours later, the plates were read at
450 nm. Relative cell viability was normalized with vehicle and pre-
sented as a fraction of the vehicle.
GSH Assay
A total of 4 × 105 cells were plated onto 60-mm tissue culture plates
in 5 ml of medium and were allowed to incubate overnight. The
medium was removed, and fresh medium was added containing the
desired concentrations of AAP, CDDP, and/or NAC. At the appropriate
time point, both the attached and detached cells were collected, washed
with PBS, and resuspended in PBS containing 1 mM EDTA. The
mixtures were then vortexed, freeze-thawed twice, and centrifuged at
10,000g for 15 minutes at 4°C. The supernatants were analyzed for
GSH concentration using a Quanticrom Glutathione Assay Kit from
BioAssay Systems (Hayward, CA) according to the manufacturer’s pro-
tocol. The protein content was determined using a BCA assay kit
(Pierce Biotechnology, Rockford, IL), and results were normalized for
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total protein concentration. Cellular GSH levels were also monitored
and analyzed using the ThiolTracker Violet GSH detection reagent
(Invitrogen/Molecular Probes, Eugene, OR) according to the manufac-
turer’s protocol. Cells were seeded in a six-well plate, incubated over-
night, and treated the following day. After designated treatment times,
the cells were washed with PBS and incubated in Dulbecco’s PBS con-
taining 10 μM (final concentration) ThiolTracker Violet for 30minutes
at 37°C. Then the cells were viewed using a Zeiss Observer fluorescent
microscope, and photographs of representative cells were taken by a
Zeiss AxioCam camera (Maple Grove, MN).
Western Blot Analysis
The cellular protein level among the different cell types and/or
different treatments was measured by Western blot analysis following
a previously outlined protocol [25]. Briefly, cells were seeded, treated
the following day, and allowed to incubate for the designated time
before being collected, washed with PBS, and centrifuged (2000g
for 5 minutes). The cells were then resuspended in a lysing buffer
(0.138 M NaCl, 0.0027 M KCl, pH 7.4, 1% nonionic detergent
[Igepal CA-630], 100 mM phenylmethylsulfonyl fluoride, and protease
inhibitor cocktail [Calbiochem, Germany]), and the protein content of
the resulting solution was quantified using a BCA kit, as described pre-
viously. The samples were then diluted into a loading buffer (120 mM
Tris-HCl pH 6.8, 4% SDS, 20% glycerol, 10% 2-mercaptoethanol,
0.002% bromophenol blue), incubated at 95°C for 5 minutes, and
separated on a 7% or 12% polyacrylamide gel (25 μg protein per well)
under reducing conditions. The separated proteins were then transferred
to a nitrocellulose membrane. The membrane was incubated with pri-
mary antibody for 1 hour at 25°C, washed with TBST (10 mM Tris-
HCl, 150 mM NaCl, pH 7.5 and 0.1% Tween-20), and incubated
for 1 hour with a peroxidase-labeled rabbit anti–mouse immunoglobulin
G antibody (1:5000 dilution; Molecular Probes).
The following primary antibodies were used: Rabbit anti-PARP
polyclonal antibody from Cell Signaling that cross-reacts with human,
rat, and mouse was used at a 1:1000 dilution. Mouse anti–β-tubulin
monoclonal antibody from Sigma-Aldrich that cross-reacts with human,
rat, mouse, monkey, and chicken was used at a 1:5000 dilution. Rabbit
anti-CYP2E1 polyclonal antibody from Stressgen that cross-reacts with
human, rat, mouse, dog, monkey, guinea pig, and horse was used at a
1:1000 dilution.
Signals were detected using a Chemiluminescence Blotting Substrate
Kit (Roche Diagnostics, Mannheim, Germany) according to the manu-
facturer’s protocol. Quantification of the immunoblot signal of respec-
tive proteins (cleaved PARP, CYP2E1, and tubulin) was performed
using UN-SCAN-IT Gel software (Silk Scientific, Inc, Orem, UT).
In Vivo Toxicology and Pharmacology Studies
Normal animal studies were performed in accordance with guide-
lines established by the Oregon Health & Science University’s Insti-
tutional Animal Care Committee. A dose-response study of AAP on
serum AAP concentration was performed. Female Long-Evans rats were
administered 0, 300, 600, and 1000 mg/kg (0, 2.1, 4.2, and 7 g/m2,
respectively) AAP intraperitoneally (IP); blood was collected at 0.5,
1, 2, and 4 hours after treatment. Serum samples were obtained by
centrifugation, and AAP concentration was determined using an AAP
direct ELISA (Immunalysis Corp, Pomona, CA). The in vivo effect of
AAP on GSH level was also investigated. Female Long-Evans rats were
placed under isoflurane anesthesia and then administered an IP dose of
either a vehicle DMSO solution or AAP at 1000 mg/kg (approximately
7 g/m2). The rats were allowed to recover, and then 6 hours after treat-
ment, the animals were killed and whole blood, liver, and brain were
harvested to test for GSH levels. GSH levels were analyzed using
a Quanticrom Glutathione Assay Kit (BioAssay Systems) as described
in a previous paragraph.
Statistical Analysis
The results were expressed as mean ± SEM, and the significance of
the difference between the mean values of treated cells/animals and
controls was determined by the Student’s t test. The level of significance
was corrected bymultiplying the P value by the number of comparisons
performed (n) according to Tukey’s correction. For data analysis, two-
way analysis of variance test was performed by comparing the different
arms of treatment of the two variables. Significance was determined
at the 5% level, two-sided. Statistical significance between treatment
and control (or vehicle) group or any two other groups was indicated
by asterisks: *P < .05 or **P < .01.
Results
AAP Reduced Cellular GSH Levels in HB Cells, Which
Was Reversed by NAC Administration In Vitro
The effects of AAP and NAC on intracellular GSH levels were deter-
mined using a QuanticromGlutathione Assay Kit and the ThiolTracker
Violet GSH detection reagent. AAP reduced GSH levels in a dose-
dependent manner in HUH6 HB cells. When controlling for total
protein concentration, 5 mM AAP lowered intracellular GSH levels
by 11% and 20 mM AAP lowered levels by 38%. NAC, a GSH pre-
cursor, reversed this effect when given in conjunction with AAP and
raised GSH levels in HUH6 cells roughly two-fold when administered
independently (Figure 1). Indeed, as in Figure 1, we found that NAC
(1 mg/ml) blocked GSH reduction even at high concentrations of AAP
(20 mM; last right gray bar) when compared with the DMSO alone
vehicle control ( first left open bar).
Furthermore, it was demonstrated that 20 mM AAP reduces intracel-
lular GSH levels within 1 hour, with no significant difference in GSH
concentration measured at 1, 2, 5, 8, or 18 hours post–20 mM AAP
treatment (Figure 2A). However, 10 mM AAP lowered intracellular
GSH levels more gradually, taking 4 hours to significantly reduce the
levels in HUH6 cells (Figure 2B). Similar results were obtained for
HepT1 cells, although in this line, untreated cells had relatively higher
baseline levels of intracellular GSH. In addition, GSH levels did not
increase as substantially in HepT1 cells treated with NAC (data not
shown). Interestingly, CDDP administered independently had no sig-
nificant effect on GSH levels, although cells treated with both CDDP
and AAP had lower levels of GSH after treatment in comparison to
those treated with AAP alone.
Acetaminophen Synergistically Increased CDDP-Induced
Cytotoxicity in HB Cells
To determine the cytotoxic effects of a combination chemotherapy
regimen, a WST-1 cell viability study was performed on cells treated
with CDDP, NAC, and/or AAP. As shown in Figure 3A, HepT1 cells
treated with 5 μg/ml CDDP in combination with 10 mM AAP had a
relative viability of 26%, whereas cells receiving CDDP or AAP alone
had relative viabilities of 58% and 60%, respectively. Similar results
were obtained for HUH6 cells (data not shown). Western blot analysis
for cleaved PARP was performed to determine the levels of apoptosis in
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Figure 1. Acetaminophen reduced cellular GSH levels in HUH6 cells in a dose-response manner. (A) HUH6 cells were treated with 5, 10, or
20 mM AAP, with or without 1 mg/ml of NAC, and collected the following day (n = 3, mean ± SEM). GSH levels were analyzed using a
Quanticrom Glutathione Assay Kit and normalized for protein concentration. (B) HUH6 cells were treated with AAP and then were stained
using a ThiolTracker Violet dye from Invitrogen. Shown are representative pictures of cells from each treatment group. Statistical signifi-
cance between treatment and control group was indicated by asterisks: *P < .05 or **P < .01.
Figure 2. Time course of GSH depletion in HB cells by AAP in vitro. (A) HepT1 and HUH6 HB cells were treated with 20 mM AAP at
time 0, collected at various times thereafter, and analyzed for GSH content with a Quanticrom Glutathione Assay Kit (n = 3, mean ±
SEM). (B) HUH6 cells were treated with 10 mM AAP and stained with ThiolTracker Violet dye at various time points. Also shown are cells
treated with both 1 mg/ml NAC and 10 mM AAP and allowed to incubate overnight. Shown are representative pictures of each treatment
group. Statistical significance between treatment and control group was indicated by an asterisk: *P < .05.
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cells receiving the various treatments. It was determined that 5 μg/ml
CDDP in combination with 10 mM AAP induced significantly more
apoptosis in both HepT1 (Figure 3B) and HUH6 cells (Figure 4A)
than either AAP or CDDP alone. In Figure 3C , the signal intensity
of cleaved PARP protein significantly (P < .01) increased in AAP +
CDDP–treated group compared with either AAP- or CDDP-alone
group. We found that the addition of AAP enhanced CDDP-induced
apoptosis in both HB cell lines. Interestingly, similar results were found
in a mouse in vivo animal study; however, HUH6 instead of HepT1
tumors had a better response to AAP and CDDP combination treat-
ment (Warmann et al., unpublished in vivo data). This effect was in-
dependent of CYP2E1 expression, which suggests possible alternative
mechanisms of AAP-induced oxidative stress and cytotoxicity in HB
cancer cells.
NAC Reduces Apoptosis in HB Cell Lines Exposed to a
Combination of AAP and CDDP
NAC was tested to determine whether it could prevent AAP and
CDDP–induced cytotoxicity. When all drugs were administered
simultaneously, the WSTand Western blot analysis for cleaved PARP
indicated that 1 mg/ml NAC is at least partially effective in reversing
the cytotoxic effects of the various treatment regimens. In Figure 4, A
and B, the presence and signal intensity of cleaved PARP show that
NAC significantly (P < .05) lowered apoptosis induced by the combi-
nation of AAP and CDDP when added simultaneously 1 or 2 hours
after but not 4 hours after the induction. Similar results were found
in a WST cell viability assay, which showed the protective effect of
NAC at 0 hour (65.0 ± 2.5% relative viability), 2 hours (49.9 ±
2.5%), and 6 hours (37.4 ± 1.6%) after the combination AAP and
CDDP (26.4 ± 2.9%) treatment (Figure 4C). The in vitro protective
effect of NAC on the AAP + CDDP–induced apoptosis of HB cells
was dependent on the time of NAC administration in different assays
used to quantify cell viability.
In Vivo Pharmacology and Toxicology Studies
Rats were administered 0, 300, 600, or 1000 mg/kg (∼0, 2, 4 and
7 g/m2) AAP with serum levels of AAP checked at 0.5, 1, 2, and
4 hours after administration. Rats administered 1000 mg/kg (∼7 g/m2)
AAP had peak serumAAP levels of 931.9 ± 98.9μg/ml at 1 hour, whereas
rats administered 300 and 600 mg/kg (∼2 and 4 g/m2) achieved peak
plasma levels of 292.5 ± 40.2 and 605.6 ± 136 μg/ml at 0.5 hour after
administration (Figure 5A). As already reported, brief exposure of animals
to isoflurane did not significantly affect the activity of liver CYP2E1 [26],
and thus, it was unlikely to have substantially biased the AAP pharmaco-
kinetic study. Further, the levels of GSH were measured in the blood
and in tissue samples from the brain and liver of treated and untreated
Figure 3. Acetaminophen synergistically enhanced CDDP-induced cytotoxicity of HB cells in vitro. (A) HepT1 cells seeded in a 96-well plate
were treated with 5 μg/ml CDDP, 10 mM AAP, and/or 1 mg/ml NAC and allowed to incubate overnight. Ten microliters of WST reagent was
then added to each well, and the plate was incubated in normal culturing conditions at 37°C for 2 hours. The plates were read using a UV
spectrometer at 450 nm. Results shown are normalized relative to the vehicle (n = 3, mean ± SEM). Statistical significance between treat-
ment and control group was indicated by asterisks: *P < .05 or **P < .01. (B) Western blot analysis for levels of PARP and cleaved PARP
was performed to measure apoptosis in the treated cells. Tubulin protein detection was used to confirm and normalize equal protein load-
ing. (C) Quantification of the immunoblot signal of cleaved PARP in panel B was performed using UN-SCAN-IT Gel software (Silk Scientific)
from three independent experiments. Statistical significance between two treatment groups was indicated: **P < .01.
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rats. GSH levels were reduced in the liver of treated rats compared with
vehicle. GSH levels in whole blood and the brain did not significantly
differ between treated and untreated animals (Figure 5B).
In Vitro Analysis of CYP2E1 Protein Levels in
Different Species
Testing the hypothesis that AAP overdose toxicity is highly depen-
dent on the animal model, we found different CYP2E1 levels in normal
hepatocytes among three different species (human, rat, and mouse).
The CYP2E1 level in normal hepatocytes was measured in the follow-
ing order: human < rat < mouse (Figure 6A). When the immunoblot
signal was normalized to tubulin level, the CYP2E1 protein level found
in rat and mouse hepatocytes was 4.9- and 6.4-fold higher, respectively,
than normal human hepatocytes (Figure 6B). In addition, HB HepT1
cells expressed a high level of CYP2E1, relative to HepG2 and HUH6
cells, where CYP2E1 protein was not detected. We found that CYP2E1
protein level varied among different cell types and different species
(Figure 6B). However, hepatocarcinoma and HB cells used in this study
were responsive to AAP treatment, and drug sensitivity was not corre-
lated to the CYP2E1 protein level.
Discussion
Acetaminophen and other nonsteroidal anti-inflammatory drugs have
been extensively evaluated for their preventative role in cancer. How-
ever, their use as a chemotherapeutic agent has been less thoroughly
explored. AAP has been evaluated multiple times in hepatocellular
carcinoma cell lines that have shown AAP-induced toxicity but interest-
ingly has not been rescued with NAC [12]. Glioma cell lines have also
been evaluated, and AAP has consistently shown toxic effects in culture
[27,28]. Breast cancer cell lines have been evaluated with mixed results
[29,30]. More recently, the combination of doxorubicin and AAP was
attempted in cell culture. This study showed that AAP was cytoprotec-
tive for HepG2 cell lines when combined with doxorubicin [31].
Treatment options for patients that present with unresectable ormetas-
tatic HB remain limited, with 25% to 30% of these patients resistant to
standard chemotherapeutic regimens. Thus, alternative approaches to
treatment are needed. Kobrinsky et al. [24] described a case report of
the successful treatment of a patient with a doxorubicin- and CDDP-
resistant HB with high-dose AAP and CDDP rescued with 8 hours of
delayed NAC administration. In this study, we have demonstrated that
a combined regimen of CDDP and AAP has enhanced cytotoxicity
Figure 4. Delayed administration of NAC exhibits decreased levels of protection against AAP and CDDP–induced cytotoxicity. (A) Western
blot analysis of HUH6 cells detecting cleaved PARP as a marker for apoptosis and tubulin to confirm equal protein loading. Five micrograms
of CDDP per milliliter and/or 10 mM AAP was added at time 0, and 1 mg/ml NAC was added at times 0, 1, 2, and 4 hours. Cells were
incubated in treated medium overnight. (B) Quantification of the immunoblot signal of cleaved PARP in panel A was performed from three
independent experiments. Statistical significance between two treatment groupswas indicated by asterisks: *P< .05 or **P< .01. (C)WST
cell viability assay of HepT1 cells. All cells were treated with 5 μg/ml CDDP and 10 mM AAP at time 0, and then either no NAC, or 1 mg/ml
NAC at 0, 2, or 6 hours (n = 3, mean ± SEM). Cells were incubated in treated medium overnight before being developed for analysis.
Statistical significance between treatment and “No NAC” control group was indicated by asterisks: *P < .05 or **P < .01.
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against HepT1 and HUH6 HB cells relative to CDDP alone in vitro.
Posadas et al. [15] reported that AAP potentiated staurosporine-induced
cell death in SH-SY5Y human neuroblastoma cell by reducing the GSH
level. Further, the rescue agent and antioxidant NAC, when adminis-
tered concurrently, acts to at least partially reverse the cytotoxicity of treat-
ments consisting of CDDP and AAP.
CDDP is a commonly prescribed anticancer drug, and its cyto-
toxicity has recently been linked to the inhibition of thioredoxin
reductase activity, an enzyme thought to help cells protect against
oxidative stress caused by hydroperoxides [32]. That CDDP cyto-
toxicity proceeds through a mechanism involving oxidative stress is sup-
ported by studies that show an inverse relationship of CDDP toxicity
and intracellular GSH levels [33]. AAP is also thought to damage both
normal and cancer cells through mechanisms involving oxidative stress.
Intracellularly, AAP is thought to be activated to the reactive metabo-
lite NAPQI by CYP2E1, which covalently binds proteins and DNA
within the cell, causing irreversible damage. NAPQI is detoxified by
GSH, and thus, its buildup is associated with a decrease in intracellu-
lar GSH levels [34]. Indeed, our studies demonstrated that AAP reduces
GSH levels in HUH6 and HepT1 cells within 1 hour of treatment.
However, CYP2E1 was not detected in HUH6 cells, suggesting an alter-
native mechanism of AAP-induced oxidative stress and cytotoxicity
in this cell line. Further, perhaps because both CDDP and AAP are
thought to cause oxidative stress within treated cells, NAC, an anti-
oxidant and free radical scavenger, protects against both AAP- and
CDDP-induced toxicities.
Substantial interest has been demonstrated in combining drugs, such
as buthionine sulfoxamine, 2-deoxy-D-glucose, and AAP, with CDDP
that are thought to chemosensitize the tumor cells by depleting intra-
cellular GSH levels [32]. However, before such drug combinations
can be translated to clinical trials, studies need to be performed to de-
termine their efficacy, pharmacology, and safety in preclinical settings.
In the current study, we present data that indicate that AAP enhances
CDDP cytotoxicity against human HB cell lines and that NAC acts
to reverse this effect when all drugs are administered simultaneously.
Other sulfur-containing antioxidants, such as sodium thiosulfate, dem-
onstrate protection against CDDP-mediated cytotoxicity when both
the medications are administered concurrently. However, when admin-
istration of CDDP and sodium thiosulfate is separated by 4 to 6 hours,
cytotoxicity is not compromised [35]. Further, when chemoprotectants
are administered at delayed time points, adverse effects of chemo-
therapy, such as high-frequency hearing loss, can be avoided [18]. Our
studies demonstrated that whereas NAC administered simultaneously
with CDDP and AAP protects HB cells in vitro, it does not reverse
AAP and CDDP–induced cytotoxicity when administered 4 hours after
AAP/CDDP combination.
There have been two phase 1 dose-escalation studies examining the
potential of AAP as a chemotherapeutic agent. The first study was a
phase 1 for multiple relapsed cancers. AAP was started at 6 g/m2 and
escalated in a stepwise manner to 20 g/m2. Eleven rounds of 20 g/m2
of AAP were given to five patients, without achieving a maximum tol-
erated dose [36]. AAP concentrations peaked within 4 to 8 hours of
Figure 5. In vivo studies of AAP pharmacokinetics and AAP effect on cellular GSH levels. (A) Levels of AAP in the serum of rats (n= 5 per
group) administered 0, 300, 600, or 1000 mg/kg (0, 2, 4, and 7 g/m2, respectively) AAP IP at times 0, 0.5, 1, 2, and 4 hours as measured
using a direct ELISA test. Data were expressed as mean ± SEM. The dashed line indicates the peak levels of AAP measured in the
serum of human patients during two phase 1 toxicity trials in which the patients were administered 15 to 20 g/m2 AAP [16,36]. (B) Rats
were administered an IP dose of either vehicle or AAP at 1000 mg/kg. The rats were allowed to recover, and the liver, the brain, and
whole blood were harvested for GSH levels at 6 hours after treatment (B). Statistical significance between treatment (+AAP) and control
(No AAP) group was indicated by asterisks: **P < .01.
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administration and achieved a mean peak serum concentration of
245 μg/ml (range, 95-473 μg/ml). The second phase 1 trial used a com-
bination of carmustine and AAP. AAP was escalated initially with a low
dose of carmustine. The authors noted two significant toxicities at the
20-g/m2 dose level: one patient developed a grade 3 toxicity with sig-
nificant aspartate amino transferase elevations, which resolved without
specific treatment. A second patient developed a grade 4 pulmonary
toxicity after AAP administration at 20 mg/m2. However, the patient’s
pulmonary toxicity was due to aspiration secondary to mental status
change. Because of these toxicities, the maximum tolerated dose of
AAP for this study was set at 15 g/m2 [16]. Serum AAP reached a peak
concentration of 253 μg/ml between 1 and 4 hours at the 15-g/m2 dose.
In contrast, rats in this study treated with 300, 600, and 1000mg/kg
(∼2, 4, and 7 g/m2) AAP achieved peak serum AAP levels at 292.5 ±
40.2, 605.6 ± 136, and 931.9 ± 98.9 μg/ml within 1 to 2 hours after
treatment, respectively (Figure 5A). It is also interesting to note that
rats receiving 1000 mg/kg (∼7 g/m2) AAP became very weak, shivered,
and exhibited hypothermia during treatment. This finding is consis-
tent with studies indicating that rat hepatocytes are far more sensitive
to AAP treatment than human hepatocytes [37]. In normal hepato-
cytes, we also found that rat (4.9-fold) and mouse (6.4-fold) contained
a higher level of CYP2E1 protein than human tissue (Figure 6). The
level of CYP2E1 protein expression by immunoblot analysis was found
to be negatively correlated to in vitro hepatotoxicity induced by AAP
(half maximal effective concentration: 3.8, 7.6, and 28.2 mM in
mouse, rat, and human hepatocyte cultures, respectively) [37]. These
data supported the hypothesis that the toxicity induced by AAP over-
dose greatly depends on the animal model applied. This may also be the
major reason why 15 to 20 g/m2 is a tolerated dose in humans, whereas
500 mg/kg (approximately 3.5 g/m2) is toxic to mice. Our results
exemplify the limitations of using a rat model to study the potential
of incorporating AAP into a preclinical trial of chemotherapeutic
regimens. In addition, the activity of rodent GSH S-transferase is ap-
proximately 10 to 20 times higher than that in humans [38]. Therefore,
active metabolites produced in vivo in rat would be immediately de-
toxified by GSH conjugation, which would make the prediction of
drug-induced hepatotoxicity in human more difficult by using either
rat or mouse models.
Also notable from the phase 1 clinical study of Wolchok et al. [16]
is that patients administered with up to 20 g/m2 of AAP were found
to have no drop in serum GSH levels. Similarly, we found no drop in
whole blood or brain GSH levels in rats in which substantially higher
plasma AAP levels were achieved than is clinically feasible. However,
we did observe substantial drops in GSH in the livers of the treated
rats, the organ thought to be most active in AAP metabolism. This
finding suggests that the chemoenhancement of CDDP-based chemo-
therapeutic regimens using AAP may be most effective against liver-
based tumors despite the difference of CYP2E1 protein level. All of
the human hepatocarcinoma and HB cells used in this study were re-
sponsive to AAP treatment in vitro.
In conclusion, we believe that the incorporation of AAP, an inexpen-
sive, relatively safe, and widely available drug, into CDDP-containing
chemotherapeutic regimens with 4 hours of delayed NAC administra-
tion is a promising approach to enhance the efficacy of CDDP chemo-
therapy while reducing the associated negative chemotherapy adverse
effects. Thus, this is an approach that merits further examination be-
cause the potential treatment benefits could impact not only liver-based
tumors but also various different malignancies.
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